claim: extracellular vesicle-based vaccine platform displaying native viral envelope proteins elicits a robust anti-sars-cov-2 response in human.
evidence_1: dna vaccines encoding antigens presented on evs efficiently induce t-cell responses and ev-based vaccines containing the spike (s) proteins of severe acute respiratory syndrome coronavirus (sars-cov) are highly immunogenic in mice.", "immunizations with a two component covevax vaccine, comprising dna vector (dnas-ev) primes, allowing in situ production of spike harbouring evs, and a boost using s-evs produced in mammalian cells, trigger potent neutralizing and cellular responses in mice, in the absence of any adjuvants."
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  )